SYRACUSE, N.Y. — Eric Dungey threw for 278 yards and three touchdowns, Cole Murphy kicked a tie-breaking field goal in the fourth quarter, and Syracuse stunned No. 2 Clemson 27-24 on Friday night to put a damper on the Tigers’ chances to repeat as national champions. Clemson (6-1, 4-1 Atlantic Coast Conference) had won 12...
NYS Entity Status
NYS Filing Date
DECEMBER 27, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - CIVELLO INSURANCE CONSULTING GROUP, INC.
Around the Web
- Syracuse comes out of nowhere to stun defending-champion Clemson
By Associated Press - Saturday Oct 14, 2017
- Syracuse stuns No. 2 Clemson 27-24
By John Kekis - Saturday Oct 14, 2017
SYRACUSE, N.Y. — As the celebration in the Syracuse locker room reverberated through the walls of the Carrier Dome, Clemson coach Dabo Swinney winced a little bit, dreams of a perfect season lost in a sea of orange. Eric Dungey threw for 278 yards and three touchdowns, Cole Murphy kicked a tie-breaking field goal in the fourth quarter, and Syracuse stunned No. 2 Clemson 27-24 on Friday night to put a damper on the Tigers’ hopes of repeating as national champions. Down maybe, but not completely out. The Tigers (6-1, 4-1 ACC) won the national championship last season despite a loss during the season to Pittsburgh. “Every goal is there for this team,” Swinney said.
- 'Junk Insurance' vs. 'Junk News' at the NY Times
Monday Jul 17, 2017
Why is “choice” in matters of one’s personal health suddenly a bad thing?
- ‘Too Big to Fail’ Label May Shrink for Some Firms Under Trump
By VICTORIA FINKLE - Monday Sep 4, 2017
The Trump administration is examining the use of the designation for large non-bank financial institutions, with a closely anticipated Treasury report on the matter expected next month.
- Amid Opioid Crisis, Insurers Restrict Pricey, Less Addictive Painkillers
By KATIE THOMAS and CHARLES ORNSTEIN - Monday Sep 18, 2017
Drug companies and doctors have been accused of fueling the opioid crisis, but some question whether insurers have played a role, too.
- Cancer drug research moving fast in immunotherapy field
By Michelle Fay Cortez - Tuesday Sep 5, 2017
The last few weeks have been historic in the fight against cancer. Novartis got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech company working in the field. Neither can rest on its laurels. Research in the field is moving so fast that today’s breakthroughs can easily become tomorrow’s has-beens. “I can’t think of any other therapies in oncology that have seen such rapid development,” said Rachel Webster, senior director of oncology at Decision Resources Group, a health care research and consulting firm in London.